LRP6是炭毒素进入的关键
James G Bann1, Lynette Cegelski, Scott J Hultgren
1Department of Chemistry, Wichita State University, Wichita, Kansas 67260, USA.
Cell
|March 28, 2006
概括
低密度脂蛋白受体相关蛋白6 (LRP6) 促进炭毒素进入细胞. LRP6与TEM8或CMG2一起作为一个核心受体,增强毒素内细胞分裂.
科学领域:
- 细胞生物学 细胞生物学
- 毒素进入的分子机制
- 传染病研究传染病研究.
背景情况:
- 炭毒素构成重大生物威胁,需要了解其细胞进入途径.
- 跨膜蛋白TEM8和CMG2此前被确定为炭毒素的关键受体.
- 控制高效毒素内部化的精确分子机制仍然不完全理解.
研究的目的:
- 阐明低密度脂蛋白受体相关蛋白6 (LRP6) 在炭毒素内细胞突变中的作用.
- 研究LRP6与已知的炭毒素受体结合的潜在核心受体功能.
主要方法:
- 基于细胞的测定用于研究毒素吸收.
- 同免疫沉以评估蛋白质相互作用.
- 显微镜可视化毒素定位和细胞进入.
主要成果:
- 发现低密度脂蛋白受体相关蛋白6 (LRP6) 显著促进了炭毒素的内细胞化.
- 作为一个核心受体,LRP6与TEM8或CMG2一起工作,以促进毒素内部化.
- 有证据表明,LRP6对于通过已知的两个受体调解的高效毒素进入至关重要.
结论:
- LRP6在细胞吸收炭毒素方面发挥着至关重要的作用.
- 鉴定LRP6作为一个核心受体扩大了我们对炭毒素进入途径的理解.
- 针对LRP6介导的途径可以为炭毒素中和提供新的策略.
相关概念视频
GPCR Desensitization
6.2K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.2K
Drug Toxicity: Overview
313
Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
313
Drug Toxicity: Risk factors
248
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
248


